Publikációink
Licensing the first reduced, 6 µg dose whole virion, aluminum adjuvanted seasonal influenza vaccine – A randomized-controlled multicenter trial
Zoltan Vajo 1, Laszlo Kalabay 2, Peter Vajo 3, Gergely Balaton 2, Noemi Rozsa 2, Peter Torzsa 2 PMID: 30497837 DOI: 10.1016/j.vaccine.2018.11.039
Dose sparing and the lack of a dose-response relationship with an influenza vaccine in adult and elderly patients - a randomized, double-blind clinical trial
Zoltan Vajo 1, Gergely Balaton 1, Peter Vajo 2, Laszlo Kalabay 1, Adam Erdman 3, Peter Torzsa 1 PMID: 28378403 PMCID: PMC5555868 DOI: 10.1111/bcp.13289
Lessons learnt from pandemic A(H1N1) 2009 influenza vaccination. Highlights of a European workshop in Brussels (22 March 2010)
Germaine Hanquet 1, Pierre Van Damme, Daniel Brasseur, Xavier De Cuyper, Simon Gregor, Martin Holmberg, Rebecca Martin, Zsuzsanna Molnár, Maria Grazia Pompa, René Snacken, Marianne van der Sande, Marc Van Ranst, Angela Wirtz, Pieter Neels PMID: 21075164 DOI: 10.1016/j.vaccine.2010.10.079
Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial
Zoltan Vajo 1, Ferenc Tamas, Laszlo Sinka, Istvan Jankovics PMID: 20018367 DOI: 10.1016/S0140-6736(09)62039-0
A single-dose influenza A (H5N1) vaccine safe and immunogenic in adult and elderly patients: an approach to pandemic vaccine development
Zoltan Vajo 1, John Wood, Lajos Kosa, Istvan Szilvasy, Gyorgy Paragh, Zsuzsanna Pauliny, Kálmán Bartha, Ildiko Visontay, Agnes Kis, Istvan Jankovics PMID: 19906909 PMCID: PMC2812344 DOI: 10.1128/JVI.01894-09
Cross-reactive immunity to clade 2 strains of influenza virus A subtype H5N1 induced in adults and elderly patients by Fluval, a prototype pandemic influenza virus vaccine derived by reverse genetics, formulated with a phosphate adjuvant, and directed to clade 1 strains
György Fazekas 1, Rita Martosne-Mendi, Istvan Jankovics, Istvan Szilvasy, Zoltan Vajo PMID: 19020111 PMCID: PMC2668277 DOI: 10.1128/CVI.00327-08
Influenza A (H5N1) pandemic prototype vaccine Fluval
Zoltan Vajo 1 PMID: 19397418 DOI: 10.1586/erv.09.25
Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children
Zoltan Vajo 1, Lajos Kosa, Istvan Szilvasy, Zsuzsanna Pauliny, Kálmán Bartha, Ildiko Visontay, Agnes Kis, Ildiko Tarjan, Noemi Rozsa, Istvan Jankovics PMID: 18978514 DOI: 10.1097/INF.0b013e3181861dd7
Yearly licensing studies from 1997 to 2007 of the inactivated whole virus seasonal influenza vaccine fluval--a useful approach to pandemic vaccine development even in less well developed countries?
Zoltan Vajo 1, Lajos Kosa, Istvan Szilvasy, Zsuzsanna Pauliny, Kálmán Bartha, Ildiko Visontay, Mate Jankovics, Agnes Kis, Istvan Jankovics PMID: 19453398 PMCID: PMC4634116 DOI: 10.1111/j.1750-2659.2008.00055.x
Inactivated whole virus influenza A (H5N1) vaccine
Zoltan Vajo, Lajos Kosa, Ildiko Visontay, Mate Jankovics, Istvan Jankovics PMID: 18044056 PMCID: PMC2738456 DOI: 10.3201/eid1305.061248
Large trials confirm immunogenicity of H1N1 vaccines
Heath Kelly 1, Ian Barr PMID: 20018366 DOI: 10.1016/S0140-6736(09)62132-2